scholarly journals Treatment of Focal Aortic Disease by Thoracic Endovascular Aortic Repair Is Associated With High Success and Low Morbidity and Mortality

2015 ◽  
Vol 62 (3) ◽  
pp. 797-798
Author(s):  
Angela Crawford ◽  
Solomon Hayon ◽  
Michael Huffner ◽  
Angelina June ◽  
Behzad Farivar ◽  
...  
2011 ◽  
Vol 54 (6) ◽  
pp. 1588-1591 ◽  
Author(s):  
Melissa L. Kirkwood ◽  
Alberto Pochettino ◽  
Ronald M. Fairman ◽  
Benjamin M. Jackson ◽  
Grace J. Wang ◽  
...  

2018 ◽  
Vol 67 (6) ◽  
pp. e195-e196
Author(s):  
Sydney Olson ◽  
Annalise Panthofer ◽  
Donald Harris ◽  
William D. Jordan ◽  
Mark A. Farber ◽  
...  

2018 ◽  
Vol 75 (6) ◽  
pp. 1575-1582 ◽  
Author(s):  
Derrick O. Acheampong ◽  
Philip Paul ◽  
Shanice Guerrier ◽  
Percy Boateng ◽  
I. Michael Leitman

2020 ◽  
Vol 59 (1) ◽  
pp. 65-73 ◽  
Author(s):  
Martin Czerny ◽  
Davide Pacini ◽  
Victor Aboyans ◽  
Nawwar Al-Attar ◽  
Holger Eggebrecht ◽  
...  

Abstract Since its clinical implementation in the late nineties, thoracic endovascular aortic repair (TEVAR) has become the standard treatment of several acute and chronic diseases of the thoracic aorta. While TEVAR has been embraced by many, this disruptive technology has also stimulated the continuing evolution of open surgery, which became even more important as late TEVAR failures do need open surgical correction justifying the need to unite both treatment options under one umbrella. This fact shows the importance of—in analogy to the heart team—aortic centre formation and centralization of care, which stimulates continuing development and improves outcome . The next frontier to be explored is the most proximal component of the aorta—the aortic root, in particular in acute type A aortic dissection—which remains the main challenge for the years to come. The aim of this document is to provide the reader with a synopsis of current evidence regarding the use or non-use of TEVAR in acute and chronic thoracic aortic disease, to share latest recommendations for a modified terminology and for reporting standards and finally to provide a glimpse into future developments.


Heart ◽  
2015 ◽  
Vol 101 (8) ◽  
pp. 586-591 ◽  
Author(s):  
Colin Bicknell ◽  
Janet T Powell

2018 ◽  
Vol 100 (8) ◽  
pp. 662-668 ◽  
Author(s):  
GJS Tan ◽  
PLZ Khoo ◽  
KMJ Chan

Introduction The development of thoracic endovascular aortic repair has altered the approach and reduced the risk of treating the majority of descending thoracic aortic conditions. Primarily developed for the exclusion of thoracic aortic aneurysms, it is now used in place of open repair surgery for most descending thoracic aortic diseases, and has also been used to treat aortic arch diseases in selected cases. Methods A literature search was conducted of Medline and Embase databases from January 2007 to February 2017, using the key words ‘aortic disease’, ‘thoracic aorta’ and ‘endovascular repair’; 205 articles were identified, of which 25 studies were selected for review based on their relevance. Findings The key findings of the indications, techniques, outcomes, complications and comparisons with open surgical repair were extracted from the published studies and are summarised in this review. Thoracic endovascular aortic repair is the preferred choice of intervention for patients with descending thoracic aortic disease. With time, it has improved to be safer and has the potential to expand aortic treatment choices in future.


2018 ◽  
Vol 67 (6) ◽  
pp. e94
Author(s):  
Alexander S. Fairman ◽  
Adam W. Beck ◽  
Mahmoud B. Malas ◽  
Philip P. Goodney ◽  
Nicholas Osborne ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-6
Author(s):  
Anja Muehle ◽  
Isil Uzun ◽  
Ziba Jalali ◽  
Ali Khoynezhad

Thoracic endovascular aortic repair (TEVAR) has become an attractive alternative treatment option for many patients with specific thoracic aortic disease. New devices and advanced image-guided procedures are continuously expanding the indications and improve neurological outcomes. Hemodynamic management of these patients is a critical aspect in reducing neurological deficit and it is different compared to patients undergoing open thoracic aortic operations. There are two different phases of blood pressure management for patients with thoracic aortic disease. Before and during the critical steps of TEVAR anti-impulsive therapy facilitates safe positioning and stent deployment. After stent grafts are deployed, controlled hypertensive blood pressure levels are achieved to avoid spinal cord ischemia. This precise blood pressure strategy is essential to ensure a safe procedure and good long-term results.


Sign in / Sign up

Export Citation Format

Share Document